Innate Pharma SA (OTCMKTS:IPHYF) Sees Significant Growth in Short Interest

Innate Pharma SA (OTCMKTS:IPHYF) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totaling 8,252 shares, a growth of 77.0% from the June 15th total of 4,661 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.

Innate Pharma Stock Performance

Shares of OTCMKTS IPHYF opened at $1.65 on Friday. Innate Pharma has a 1 year low of $1.37 and a 1 year high of $2.25. The company’s 50-day moving average is $1.75 and its 200 day moving average is $1.85.

About Innate Pharma

Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.

The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.